Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
47
VRDN Quote, Financials, Valuation and Earnings
Last price:
$28.79
Seasonality move
:
-15.82%
Day range:
$29.25 - $30.46
52-week range:
$9.90 - $34.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
34.49x
P/B ratio:
9.14x
Volume:
1.8M
Avg. volume:
1.5M
1-year change:
68.37%
Market cap:
$2.9B
Revenue:
$302K
EPS (TTM):
-$3.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
$15.8M | -$1.00 | -82.64% | -1.73% | $42.06 |
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 23.95% | 81.82% | $25.67 |
|
AVTR
Avantor, Inc.
|
$1.6B | $0.22 | -0.77% | 69.31% | $12.89 |
|
IMVT
Immunovant, Inc.
|
-- | -$0.69 | -- | -9.61% | $40.63 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.87 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
$30.07 | $42.06 | $2.9B | -- | $0.00 | 0% | 34.49x |
|
ADMA
ADMA Biologics, Inc.
|
$16.28 | $25.67 | $3.9B | 19.12x | $0.00 | 0% | 8.20x |
|
AVTR
Avantor, Inc.
|
$9.64 | $12.89 | $6.6B | 10.97x | $0.00 | 0% | 1.00x |
|
IMVT
Immunovant, Inc.
|
$25.94 | $40.63 | $5.3B | -- | $0.00 | 0% | -- |
|
MRKR
Marker Therapeutics, Inc.
|
$1.46 | $7.87 | $24.3M | -- | $0.00 | 0% | 3.96x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.27 | $5.50 | $37.3M | -- | $0.00 | 0% | 4.35x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
4.52% | 1.855 | 1.21% | 11.06x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.277 | 2.38% | 3.53x |
|
AVTR
Avantor, Inc.
|
40.92% | 1.095 | 45.33% | 0.90x |
|
IMVT
Immunovant, Inc.
|
-- | 1.837 | -- | 15.03x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 2.330 | -- | 5.66x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
$70.3M | -$40M | -46.01% | -47.79% | -56.7% | -$84.7M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
AVTR
Avantor, Inc.
|
$526.5M | $138.4M | -0.81% | -1.4% | 8.52% | $171.7M |
|
IMVT
Immunovant, Inc.
|
-$101K | -$114.4M | -73.11% | -73.12% | -- | -$92.3M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Viridian Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns VRDN or ADMA?
ADMA Biologics, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of 27.14%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About VRDN or ADMA?
Viridian Therapeutics, Inc. has a consensus price target of $42.06, signalling upside risk potential of 39.87%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 57.66%. Given that ADMA Biologics, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 ADMAADMA Biologics, Inc.3 0 0 -
Is VRDN or ADMA More Risky?
Viridian Therapeutics, Inc. has a beta of 0.962, which suggesting that the stock is 3.833% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.502%.
-
Which is a Better Dividend Stock VRDN or ADMA?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or ADMA?
Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 19.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 34.49x versus 8.20x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.34.49x -- $70.6M -$34.6M ADMAADMA Biologics, Inc.8.20x 19.12x $134.2M $36.4M
-
Which has Higher Returns VRDN or AVTR?
Avantor, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of -43.84%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Avantor, Inc.'s return on equity of -1.4%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M AVTRAvantor, Inc.32.42% -$1.04 $9.4B -
What do Analysts Say About VRDN or AVTR?
Viridian Therapeutics, Inc. has a consensus price target of $42.06, signalling upside risk potential of 39.87%. On the other hand Avantor, Inc. has an analysts' consensus of $12.89 which suggests that it could grow by 33.74%. Given that Viridian Therapeutics, Inc. has higher upside potential than Avantor, Inc., analysts believe Viridian Therapeutics, Inc. is more attractive than Avantor, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 AVTRAvantor, Inc.3 14 1 -
Is VRDN or AVTR More Risky?
Viridian Therapeutics, Inc. has a beta of 0.962, which suggesting that the stock is 3.833% less volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.874%.
-
Which is a Better Dividend Stock VRDN or AVTR?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or AVTR?
Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are smaller than Avantor, Inc. quarterly revenues of $1.6B. Viridian Therapeutics, Inc.'s net income of -$34.6M is higher than Avantor, Inc.'s net income of -$711.8M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 34.49x versus 1.00x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.34.49x -- $70.6M -$34.6M AVTRAvantor, Inc.1.00x 10.97x $1.6B -$711.8M
-
Which has Higher Returns VRDN or IMVT?
Immunovant, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of --. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Immunovant, Inc.'s return on equity of -73.12%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M IMVTImmunovant, Inc.-- -$0.61 $986.1M -
What do Analysts Say About VRDN or IMVT?
Viridian Therapeutics, Inc. has a consensus price target of $42.06, signalling upside risk potential of 39.87%. On the other hand Immunovant, Inc. has an analysts' consensus of $40.63 which suggests that it could grow by 56.61%. Given that Immunovant, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Immunovant, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 IMVTImmunovant, Inc.11 4 0 -
Is VRDN or IMVT More Risky?
Viridian Therapeutics, Inc. has a beta of 0.962, which suggesting that the stock is 3.833% less volatile than S&P 500. In comparison Immunovant, Inc. has a beta of 0.541, suggesting its less volatile than the S&P 500 by 45.89%.
-
Which is a Better Dividend Stock VRDN or IMVT?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immunovant, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Immunovant, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or IMVT?
Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are larger than Immunovant, Inc. quarterly revenues of --. Viridian Therapeutics, Inc.'s net income of -$34.6M is higher than Immunovant, Inc.'s net income of -$110.6M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Immunovant, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 34.49x versus -- for Immunovant, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.34.49x -- $70.6M -$34.6M IMVTImmunovant, Inc.-- -- -- -$110.6M
-
Which has Higher Returns VRDN or MRKR?
Marker Therapeutics, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of -162.11%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About VRDN or MRKR?
Viridian Therapeutics, Inc. has a consensus price target of $42.06, signalling upside risk potential of 39.87%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 438.81%. Given that Marker Therapeutics, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is VRDN or MRKR More Risky?
Viridian Therapeutics, Inc. has a beta of 0.962, which suggesting that the stock is 3.833% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.442, suggesting its more volatile than the S&P 500 by 44.218%.
-
Which is a Better Dividend Stock VRDN or MRKR?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or MRKR?
Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 34.49x versus 3.96x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.34.49x -- $70.6M -$34.6M MRKRMarker Therapeutics, Inc.3.96x -- $1.2M -$2M
-
Which has Higher Returns VRDN or PSTV?
Plus Therapeutics, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of -316.61%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About VRDN or PSTV?
Viridian Therapeutics, Inc. has a consensus price target of $42.06, signalling upside risk potential of 39.87%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1928.02%. Given that Plus Therapeutics, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is VRDN or PSTV More Risky?
Viridian Therapeutics, Inc. has a beta of 0.962, which suggesting that the stock is 3.833% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock VRDN or PSTV?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or PSTV?
Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 34.49x versus 4.35x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.34.49x -- $70.6M -$34.6M PSTVPlus Therapeutics, Inc.4.35x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
